ESR1 and breast carcinoma: Estrogen receptor (ER)-α activation appears in approximately 70% of breast cancer and plays a critical role in the pathogenesis of ER-α-positive breast cancer [2], making it not only an important prognostic marker and clinical outcome indicator, but also a potential therapeutic target in breast cancer.